본문 바로가기
KERD
논문KCI 등재

Predictors of Post-Chemoradiotherapy Pulmonary Complication in Locally Advanced Non-Small Cell Lung Cancer

김학재|이주호|강병희|이태훈|우홍균
대한암학회 (Korean Cancer Association)|2023.07|Cancer Research and Treatment|제55권 제3호|pp. 865-874|DOI 10.4143/crt.2022.1538

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

Lung neoplasmsChemoradiotherapyHypoalbuminaemiaPulmonary diffusing capacity
주제분류의학일반

초록

Purpose We investigated the clinical effects and predictive factors of severe post-chemoradiotherapy pulmonary complications (PCPC) in locally advanced non–small cell lung cancer (LA-NSCLC). Materials and Methods Medical records of 317 patients who underwent definitive concurrent chemoradiation (CCRT) for LA-NSCLC were reviewed retrospectively. PCPC was defined as an event of admission or emergency department visit for acute or subacute pulmonary inflammatory complications, including pneumonitis and pneumonia, within 6 months after CCRT initiation. Patient characteristics, baseline lung function tests, radiation dosimetric parameters, and laboratory tests were analyzed to investigate their association with PCPC. Prognostic endpoints were disease progression rate (DPR) and overall survival (OS). Results PCPC was reported in 53 patients (16.7%). The OS of patients with PCPC was significantly worse (35.0% in 2 years) than that of patients without PCPC (67.0% in 2 years, p < 0.001). However, 2-year DPRs were 77.0% and 70.7% in patients with and without PCPC, respectively, which were not significantly different (p=0.087). In multivariate logistic regression, PCPC was independently associated with grade ≥ 1 hypoalbuminemia during CCRT (odds ratio [OR], 5.670; 95% confidence interval [CI], 2.487 to 13.40; p < 0.001), lower diffusing capacity of carbon monoxide (DLCO) (per mL/min/mmHg; OR, 0.855; 95% CI, 0.743 to 0.974; p=0.022), and higher lung V5 (per 10%; OR, 1.872; 95% CI, 1.336 to 2.699; p < 0.001). Conclusion PCPC might be a clinical endpoint to evaluate complications and predict the survival of patients subjected to CCRT for LA-NSCLC. Hypoalbuminaemia, DLCO, and lung V5 might predict PCPC in LA-NSCLC.

Abstract

Purpose We investigated the clinical effects and predictive factors of severe post-chemoradiotherapy pulmonary complications (PCPC) in locally advanced non–small cell lung cancer (LA-NSCLC). Materials and Methods Medical records of 317 patients who underwent definitive concurrent chemoradiation (CCRT) for LA-NSCLC were reviewed retrospectively. PCPC was defined as an event of admission or emergency department visit for acute or subacute pulmonary inflammatory complications, including pneumonitis and pneumonia, within 6 months after CCRT initiation. Patient characteristics, baseline lung function tests, radiation dosimetric parameters, and laboratory tests were analyzed to investigate their association with PCPC. Prognostic endpoints were disease progression rate (DPR) and overall survival (OS). Results PCPC was reported in 53 patients (16.7%). The OS of patients with PCPC was significantly worse (35.0% in 2 years) than that of patients without PCPC (67.0% in 2 years, p < 0.001). However, 2-year DPRs were 77.0% and 70.7% in patients with and without PCPC, respectively, which were not significantly different (p=0.087). In multivariate logistic regression, PCPC was independently associated with grade ≥ 1 hypoalbuminemia during CCRT (odds ratio [OR], 5.670; 95% confidence interval [CI], 2.487 to 13.40; p < 0.001), lower diffusing capacity of carbon monoxide (DLCO) (per mL/min/mmHg; OR, 0.855; 95% CI, 0.743 to 0.974; p=0.022), and higher lung V5 (per 10%; OR, 1.872; 95% CI, 1.336 to 2.699; p < 0.001). Conclusion PCPC might be a clinical endpoint to evaluate complications and predict the survival of patients subjected to CCRT for LA-NSCLC. Hypoalbuminaemia, DLCO, and lung V5 might predict PCPC in LA-NSCLC.

참고문헌 (30)

  1. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
  2. Morgensztern D, "Trends in stage distribution for patients with non-small cell lung cancer : a National Cancer Database survey", J Thorac Oncol, 5, pp.29~33 (2010)
  3. Spigel DR, "Five-year survival outcomes from the PACIFIC trial : durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer", J Clin Oncol, 40, pp.1301~1311 (2022)
  4. Antonia SJ, "Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC", N Engl J Med, 379, pp.2342~2350 (2018)
  5. Antonia SJ, "Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer", N Engl J Med, 377, pp.1919~1929 (2017)
  6. Kuang Y, "Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer : a systematic literature review and meta-analysis", Lung Cancer, 174, pp.174~185 (2022)
  7. Luna JM, "Predicting radiation pneumonitis in locally advanced stage II-III non-small cell lung cancer using machine learning", Radiother Oncol, 133, pp.106~112 (2019)
  8. Pallis AG, "Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy", Lung Cancer, 62, pp.356~363 (2008)
  9. Akinosoglou KS, "Infectious complications in patients with lung cancer", Eur Rev Med Pharmacol Sci, 17, pp.8~18 (2013)
  10. Benjamini Y, "Controlling the false discovery rate : a practical and powerful approach to multiple testing", J R Stat Soc Series B Methodol, 57, pp.289~300 (1995)
  11. Warner A, "Factors associated with early mortality in patients treated with concurrent chemoradiation therapy for locally advanced non-small cell lung cancer", Int J Radiat Oncol Biol Phys, 94, pp.612~620 (2016)
  12. Tucker SL, "Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation", Radiother Oncol, 119, pp.495~500 (2016)
  13. Kim S, "Hypoalbuminemia and clinical outcomes : what is the mechanism behind the relationship?", Am Surg, 83, pp.1220~1227 (2017)
  14. Lai CC, "Low preoperative serum albumin in colon cancer : a risk factor for poor outcome", Int J Colorectal Dis, 26, pp.473~481 (2011)
  15. Greenblatt DY, "Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy", Ann Surg Oncol, 18, pp.2126~2135 (2011)
  16. Li P, "Perioperative changes of serum albumin are a predictor of postoperative pulmonary complications in lung cancer patients : a retrospective cohort study", J Thorac Dis, 10, pp.5755~5763 (2018)
  17. Morse RT, "Sarcopenia and treatment toxicity in older adults undergoing chemoradiation for head and neck cancer : identifying factors to predict frailty", Cancers(Basel), 14, pp.2094~ (2022)
  18. Satomi-Tsushita N, "Risk factors of severe benign cicatricial stricture after definitive chemoradiation for localized T3 esophageal carcinoma", Anticancer Res, 40, pp.1071~1077 (2020)
  19. Kang BH, "Prediction and clinical impact of delayed lymphopenia after chemoradiotherapy in locally advanced non-small cell lung cancer", Front Oncol, 12, pp.891221~ (2022)
  20. Gioulbasanis I, "The Glasgow Prognostic Score(GPS)predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer", Lung Cancer, 77, pp.383~388 (2012)
  21. Shaverdian N, "Pretreatment immune parameters predict for overall survival and toxicity in early-stage non-small-cell lung cancer patients treated with stereotactic body radiation therapy", Clin Lung Cancer, 17, pp.39~46 (2016)
  22. Nazha B, "Hypoalbuminemia in colorectal cancer prognosis : nutritional marker or inflammatory surrogate?", World J Gastrointest Surg, 7, pp.370~377 (2015)
  23. Keller U, "Nutritional laboratory markers in malnutrition", J Clin Med, 8, pp.775~ (2019)
  24. Palma DA, "Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer : an individual patient data meta-analysis", Int J Radiat Oncol Biol Phys, 87, pp.690~696 (2013)
  25. McMillan DC, "Systemic inflammation, nutritional status and survival in patients with cancer", Curr Opin Clin Nutr Metab Care, 12, pp.223~226 (2009)
  26. Kowalski-Saunders PW, "Reversible inhibition of albumin production by rat hepatocytes maintained on a laminin-rich gel(Engelbreth-Holm-Swarm)in response to secretory products of Kupffer cells and cytokines", Hepatology, 16, pp.733~741 (1992)
  27. Torre-Bouscoulet L, "Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer", Respir Res, 19, pp.72~ (2018)
  28. Gopal R, "Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer", Int J Radiat Oncol Biol Phys, 56, pp.114~120 (2003)
  29. McFarlane MR, "Predictors of pneumonitis after conventionally fractionated radiotherapy for locally advanced lung cancer", Int J Radiat Oncol Biol Phys, 111, pp.1176~1185 (2021)
  30. Prabhu RS, "Radiation therapy and neutropenia", Curr Probl Cancer, 39, pp.292~296 (2015)

관련 논문AI추천

Predictive Factors for Radiation Pneumonitis in Lung Cancer Treated with Helical Tomotherapy공문규, 김영경, 최진현, 홍성언대한암학회 · Cancer Research and Treatment2013 · 제45권 제4호Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis강진형, 김승준, 김연실, 김영균, 오세진, 유이령, 이상남, 이윤희, 이효천, 한대희, 홍숙희대한암학회 · Cancer Research and Treatment2015 · 제47권 제4호Analysis of Once-Daily Thoracic Radiotherapy Dose According to the Underlying Lung Disease in Patients with Limited-Stage Small Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy김병혁, 김수지, 김학재, 손재만, 우홍균, 정주현대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer김태규, 남희림, 노재명, 박근칠, 박승규, 선종무, 안명주, 안용찬, 안진석, 이경화, 이언주, 이혜빈, 표홍렬대한암학회 · Cancer Research and Treatment2019 · 제51권 제2호Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer강진형, 김연실, 김영균, 박재길, 안명임, 왕영필, 유이령, 윤세철, 이동수, 이상남, 장홍석, 최병옥, 한대희대한암학회 · Cancer Research and Treatment2011 · 제43권 제1호Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules노재명, 안용찬, 오동률, 조원경, 표홍렬대한암학회 · Cancer Research and Treatment2016 · 제48권 제4호

이 간행물의 다른 논문 (32건)

Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy조원경, 안용찬, 엄준원, 이종훈, 정재욱, 임채홍, 조현민, 유규상, 지의규pp. 707-719Cellular Dormancy in Cancer - Mechanisms and Potential Targeting Strategies이호영, 민혜영pp. 720-736Identification of Genes Involved in EGF-Induced Apoptosis Using CRISPR/Cas9 Knockout Screening: Implications for Novel Therapeutic Targets in EGFR-Overexpressing Cancers이주호, 전승혁, 김용섭, 전상록, 김재식, 우홍균pp. 737-745Immunogenicity and Safety of Vaccines Against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study이충근, 박소라, 김규현, 안진영, 이연정, 염준섭, 정민규, 라선영, 김신영, 신상준, 김정호, 이경화, 정수진, 최준용, 구남수, 범승훈, 백예지pp. 746-757Recent Trends of Medical Expenses Associated with Radiation Therapy in Korea Based on HIRA Big Data허승재, 박원, 안용찬, 양경미, 이정은pp. 758-765
원문 보기